Catalog No.
Product Name
Application
Product Information
Citations
-
Anti-CCR2 Antibody
Minokitug is a humanized monoclonal antibody that specifically targets the CCR2 protein. It exhibits significant biological activity by inhibiting CCR2-mediated signaling pathways, making it a valuable tool for studying inflammatory processes. This reagent is particularly relevant in research focused on refractory or relapsed ulcerative colitis, aiding in the understanding of the disease's pathophysiology and potential therapeutic interventions. -
CCR2 PROTAC Degrader
LUF7996 is a potent CCR2 PROTAC degrader that selectively targets and degrades CCR2 with a DC50 value of 2.6 μM. This compound effectively engages with the E3 ligase cereblon, promoting sustained and concentration-dependent degradation of CCR2 via the lysosomal pathway. LUF7996 is particularly valuable for research applications involving the inhibition of monocyte migration in vitro, facilitating studies in inflammation and immune response modulation. -
CCR1 Antagonist
cis-J-113863 is a competitive antagonist of chemokine receptor 1 (CCR1) that exhibits potent inhibitory effects, with IC50 values of 0.9 nM for human CCR1 and 5.8 nM for mouse CCR1. This compound is valuable for research in inflammation, immune response, and related therapeutic areas, facilitating the investigation of CCR1's role in various biological processes and disease models. -
CCR1 Antagonist
CCR1 antagonist 13 is a selective antagonist of the CCR1 chemokine receptor. This small molecule inhibitor effectively disrupts CCR1 signaling, making it a valuable tool for investigating the roles of CCR1 in inflammatory responses and immune cell migration. Its applications extend to research on autoimmune diseases, chronic inflammatory conditions, and the modulation of chemokine-mediated pathways. -
CCR2 Inhibitor-DOTA Conjugate
DOTA-ECL1i is a CCR2 inhibitor conjugated with DOTA, designed for use in positron emission tomography (PET) imaging. When radiolabeled with 68Ga, DOTA-ECL1i provides a specific PET tracer that targets CCR2 expression in various pathological conditions. This compound is applicable in research focused on pulmonary fibrosis, cardiac injury, abdominal aortic aneurysm inflammation, atherosclerosis, and cancers of the head, neck, and pancreas. -
CCR6/CXCR2 Antagonist
SQA1 is a squaramide derivative that functions as a CCR6 and CXCR2 antagonist, displaying a dissociation constant (Kd) of 250 nM. It effectively occupies the intracellular pocket, overlapping with the G protein binding site, which helps stabilize the closed conformation of the receptor. This compound is useful in research applications targeting chemokine receptor signaling pathways and their roles in inflammatory responses and immune cell trafficking. -
CCR2 Antagonist
CCR2 Antagonist 6 is a potent CCR2 antagonist with a Ki value of 0.215 μM for CCR2 and 0.174 μM for human CCR2B. This compound exhibits significant biological activity by inhibiting the CCR2 receptor, making it a valuable tool for studying inflammatory processes and autoimmune diseases. Its specificity and efficacy contribute to the understanding of CCR2-related pathways in various pathophysiological conditions. -
CCR5 Antagonist
CCR5 antagonist 5 is an effective CCR5 antagonist that targets the CCR5 receptor, playing a critical role in modulating immune response and inflammation. This compound is particularly valuable for research applications focused on HIV infection and other viral pathogens, offering insights into therapeutic strategies for immunological disorders and viral disease management. -
CCR9 Modulator
CCR9 modulator-1 is a selective modulator of the chemokine receptor CCR9, primarily involved in T-cell trafficking and immune response regulation. This compound demonstrates significant potential in influencing CCR9-mediated immune pathways, making it a valuable tool for the study of inflammatory diseases such as Crohn's disease and other gastrointestinal disorders. Researchers can utilize CCR9 modulator-1 to explore therapeutic strategies targeting CCR9 in various immunological contexts. -
CCR1/CCR3 Antagonist
trans-J-113863 is a potent antagonist of the CCR1 and CCR3 chemokine receptors. It effectively inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants, exhibiting IC50 values of 9.57 nM and 93.8 nM, respectively. This compound serves as a valuable tool for research focused on inflammation and immune responses, offering insights into the roles of these receptors in various biological contexts. -
CCR8 Antagonist
CCR8 antagonist 3 is a selective antagonist of the CCR8 receptor, exhibiting an IC50 value of 0.062 µM. This compound demonstrates stability in human microsomes, making it suitable for various in vitro studies. Its potential applications include exploring mechanisms of immune response modulation and investigating therapeutic strategies for inflammatory diseases and cancer. -
CCR5/CXCR3 Inhibitor
CCR5/CXCR3-IN-1 is a potent inhibitor of the chemokine receptors CXCR3 and CCR5. This compound effectively suppresses the chemotaxis of transformed cells expressing CCR5 and CXCR3, while exhibiting no inhibitory effect on CXCR4-expressing transfected cells. CCR5/CXCR3-IN-1 is valuable for research into chronic arthritic rheumatism and other conditions where modulation of these receptors is crucial. -
CCR1 Antagonist
CP-865569 is a potent CCR1 antagonist, specifically designed to inhibit the activity of the CCR1 chemokine receptor. This compound demonstrates potential therapeutic effects in the modulation of inflammatory responses, making it valuable for research into inflammatory and autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. Its ability to selectively target CCR1 makes CP-865569 an important tool for investigating the roles of chemokines in disease pathology and therapeutic intervention. -
CCR1 Antagonist
BMS-457 is a potent and selective antagonist of the chemokine receptor CCR1. This compound demonstrates significant biological activity in modulating inflammatory pathways and is primarily utilized in research applications related to rheumatoid arthritis. Its ability to inhibit CCR1 makes it a valuable tool for studying the role of chemokines in autoimmune disorders. -
CCR5 Antagonist
SCH 350581 is a CCR5 antagonist that effectively inhibits HIV-1 replication. By obstructing viral entry into host cells and preventing the binding of the gp120 protein to primary lymphocytes, SCH 350581 plays a critical role in studying HIV-1 pathogenesis and potential therapeutic interventions. This compound is valuable for research applications focused on antiviral drug development and the mechanisms of HIV entry. -
CCR8 Antagonist
AZ760 is a potent antagonist of the CCR8 receptor, which plays a significant role in immune response modulation. This compound demonstrates excellent potency and favorable lipophilicity, resulting in a high free fraction in blood. However, it is important to note that AZ760 exhibits unacceptable inhibition of the hERG potassium channel, which may have implications for cardiovascular safety in therapeutic applications. -
Asperlicin
Asperlicin D is an metabolite derived from the Aspergillus alliaceus strain (ATCC 20656), primarily involved in the regulation of fungal biosynthesis. It exhibits antifungal and antibacterial activities through inhibition of various biological pathways. Due to its potential therapeutic properties, Asperlicin D is of interest in studies related to natural product chemistry and antimicrobial drug development. -
CXCR2/CCR7 Antagonist
CCR7 antagonist 1 is a potent dual antagonist of CXCR2 and CCR7, exhibiting an IC50 of 11.02 μM for CXCR2 and 0.43 μM for CCR7. This compound demonstrates significant inhibition of chemokine receptor signaling, making it valuable for studying inflammatory responses and immune system modulation. Its application spans various fields, including cancer research and autoimmune disease studies, where targeting these receptors can provide insights into disease mechanisms and potential therapeutic strategies. -
CCR7 Antagonist
SLW131 is a potent CCR7 antagonist, demonstrating a high affinity with a Ki value of 9.85 nM. This compound effectively inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM, as well as β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 also disrupts CCL19-induced morphological alterations in primary bone marrow-derived dendritic cells and impedes CCR7-mediated migration in mouse CD4+ T cells, making it a valuable tool for research in immune response and cell signaling pathways. -
HIV Inhibitor Prodrug
HIV-IN-13 prodrug is designed as a prodrug of an HIV inhibitor, engaging specifically with viral components upon conversion. In the presence of glutathione (GSH), this compound exhibits significant antiviral activity, demonstrating EC50 values of 10 μM and 8.2 μM against HIV-1 at concentrations of 1 mM and 2 mM GSH, respectively. This prodrug serves as a valuable tool for research focused on HIV infection and therapeutic development. -
HIV Substrate
Fluorescent HIV Substrate is specifically designed to facilitate the study of HIV protease activity. This highly sensitive substrate emits fluorescence upon cleavage by the HIV protease, enabling real-time monitoring of enzymatic activity. It serves as an essential tool in HIV research, helping to evaluate protease inhibitors and advance therapeutic strategies against HIV infection. -
HIV-1 Inhibitor
NB-64 is an orally active inhibitor of HIV-1 that targets viral replication. Its significant antiviral activity makes it a valuable tool for research into HIV infections and the development of therapeutic strategies. This compound contributes to a better understanding of HIV pathogenesis and potential treatment options. -
HIV Inhibitor
PNU-142721 is a reverse transcriptase inhibitor that targets HIV by effectively inhibiting various type I variants. This compound serves as a valuable tool in HIV research, particularly in the study of viral replication and resistance mechanisms. Its dual function as a PXR agonist further enhances its relevance in investigating drug metabolism and therapeutic strategies against HIV. -
HIV Integrase Inhibitor
Lepetegravir is a potent HIV integrase inhibitor that exerts its antiviral effects by blocking the integration of viral DNA into the host genome. With an EC50 value of 0.98 nM in MT-4 cells, it demonstrates strong efficacy in suppressing HIV replication. Lepetegravir is applicable in research aimed at understanding HIV pathogenesis and developing antiretroviral therapies. -
Anti-HIV Agent
NYAD-13 is an anti-HIV agent that demonstrates antiviral activity against HIV-1 IIIB. While it shows potential in inhibiting viral replication, it is important to note that it also exhibits significant cytotoxicity. This compound may be useful in research focused on understanding the mechanisms of HIV infection and evaluating antiviral strategies. -
HIV-1 Integrase Inhibitor
Integracin B is a potent inhibitor targeting HIV-1 integrase through a dimeric alkyl aromatic structure. It effectively inhibits both the coupled and strand transfer activities of the integrase, making it a valuable tool for studying HIV-1 replication and integration processes. This compound is suitable for research applications focused on antiviral drug development and the mechanistic understanding of integrase-mediated viral entry. -
Control of Anti-HIV Agent
Marsdenoside F is a polyoxygenated pregnane glycoside derived from the stems of Marsdenia tenacissima, primarily targeting anti-HIV applications. In biological assays, Marsdenoside F demonstrated negligible cytotoxicity toward A549 and MCF-7 cell lines, as well as a lack of significant anti-HIV activity. Its properties make it a candidate for further research in the context of HIV treatment and cell line studies. -
HIV Inhibitor
HIV-1 Inhibitor-9 is a potent inhibitor targeting HIV-1, effectively inhibiting both wild-type and various non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant strains at low nanomolar concentrations. This compound demonstrates significant antiviral activity, making it a valuable tool for research into HIV treatment and drug resistance mechanisms. Its efficacy against resistant strains supports its potential use in therapeutic studies and drug development efforts aimed at combating HIV-1 infection. -
Reverse Transcriptase Inhibitor
Inophyllum B is a potent inhibitor of HIV reverse transcriptase, exhibiting an impressive IC50 value of 38 nM. This compound effectively inhibits HIV-1 in vitro cell cultures with an IC50 of 1.4 μM. Inophyllum B is isolated from the acetone extract of the giant African snail, Achatina fulica, making it a valuable reagent for research applications focused on antiviral drug development and the mechanisms of HIV replication. -
HIV Inhibitor
Tripterifordin is a potent inhibitor of HIV replication, specifically targeting H9 lymphocyte cells. It demonstrates significant anti-HIV activity with an EC50 value of 3100 nM. This compound is valuable for research applications aimed at understanding HIV pathogenesis and developing therapeutic strategies against HIV infection. -
CCR5 Antagonist
PF-232798 is an orally bioavailable antagonist of the CCR5 receptor, primarily known for its role in HIV entry into cells. By blocking CCR5, PF-232798 demonstrates efficacy in inhibiting HIV replication and offers potential applications in antiviral research. Its selective activity makes it a valuable tool for studying HIV pathogenesis and developing new therapeutic strategies against the virus. -
HIV Inhibitor
UK-88947 hydrochloride is a potent HIV protease inhibitor, primarily targeting HIV-1 replication. It effectively disrupts the early stages of the viral life cycle when administered to cells prior to infection. Additionally, UK-88947 hydrochloride inhibits viral protease activity during infection, thereby significantly impacting viral replication. This compound is valuable for research focused on developing therapeutic strategies against HIV. -
HIV Inhibitor
(D-Ala)-Peptide T is an octapeptide that acts as an HIV inhibitor by targeting the HIV-1 envelope glycoprotein gp120. This compound has been shown to release chemokines and protect against neuronal death induced by gp120. It is a valuable reagent for research into infectious diseases and neurological disorders, particularly AIDS-related dementia. -
Anti-HIV Agent
KP-1461 is a nucleoside derivative that acts as an anti-HIV agent by inducing lethal mutations in the viral genome. This compound has significant potential for research applications focused on HIV infection and the development of novel antiviral strategies. It is valuable for studies aimed at understanding the mechanisms of viral resistance and the efficacy of mutation-inducing therapies. -
HIV-1 Inhibitor
HIV-1 Inhibitor-29 is a potent inhibitor targeting the HIV-1 virus, demonstrating an EC50 of 2.18 μM against the HIV-1 IIIB strain. This compound exhibits significant anti-resistance properties against the F227L/V106A mutant strain, with an EC50 of 0.974 μM, while maintaining low cytotoxicity in MT-4 cells (CC50 = 211 μM). HIV-1 Inhibitor-29 is a valuable tool for research focused on AIDS and HIV-1 therapeutic development. -
Non-Nucleoside rReverse Transcriptase Inhibitor
UC-84 (NSC-615985) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent anti-HIV activity. By targeting the reverse transcriptase enzyme, UC-84 effectively disrupts viral replication, making it a valuable compound for HIV research. Its application extends to studies focused on the mechanisms of viral resistance and the development of novel therapeutic strategies against HIV. -
HIV-1 TAR RNA Binder
WRNA10 is a potent HIV-1 TAR RNA binder that exhibits an IC50 of 10 µM, demonstrating its efficacy in inhibiting interactions with the TAR RNA structure. With a CC50 value of 40 µM, WRNA10 serves as a valuable tool for studying HIV-1 RNA functionalities and therapeutic approaches targeting HIV-1 infections. Its precise binding affinity and biological activity make it suitable for research applications in virology and antiviral drug development. -
HIV-1 Inhibitor
NNRT-IN-1 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor targeting HIV-1. This compound demonstrates significant anti-resistance efficacy, effectively inhibiting wild-type HIV-1 as well as five mutant strains, with EC50 values in the nanomolar range. Additionally, NNRT-IN-1 exhibits favorable pharmacokinetic properties, making it a valuable tool for research applications in HIV therapeutics. -
HIV Inhibitor
(+)-Carbovir is a nucleoside analog specifically designed to inhibit human immunodeficiency virus type 1 (HIV-1). Its enhanced chemical and metabolic stability contributes to its antiviral efficacy. This compound serves as a valuable tool in AIDS research, facilitating studies aimed at understanding and combating HIV infection. -
HIV-1 RT Inhibitor
Tivirapine is a non-nucleoside inhibitor targeting HIV-1 reverse transcriptase (RT), demonstrating potent antiviral activity with an EC50 value of 4 nM. This compound effectively inhibits the Y181C mutant of HIV-1 RT, offering a valuable tool for studying drug resistance mechanisms and evaluating therapeutic strategies against HIV-1 infection. Its application is relevant in both basic research and development of novel antiviral therapies. -
HIV-1 Inhibitor
HIV-1 inhibitor-64 (Compound 7c) is a potent antagonist targeting HIV-1, demonstrating effective inhibition of both wild-type and resistant mutants, specifically E138K/Q148K and G140S/Q148R, with EC50 values of 62.5 nM and 11.3 nM, respectively. This compound exhibits significant antiviral activity, making it a valuable tool for AIDS research and studies focused on HIV-1 resistance mechanisms. -
HIV
(Threo)-Indinavir is a potent protease inhibitor targeting HIV-1, crucial for the management of HIV/AIDS. By obstructing the viral protease activity, (threo)-Indinavir effectively disrupts viral replication. This compound is commonly utilized as part of highly active antiretroviral therapy (HAART) for the suppression of HIV viral load in infected individuals. -
HIV-1 Inhibitor
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1 with an EC50 of 1.9 nM, demonstrating potent antiviral activity. This compound exhibits minimal interaction with cytochrome P450 enzymes, with IC50 values of 5.16 μM for CYP2C9 and 4.51 μM for CYP2C19, indicating its favorable profile for therapeutic applications. Notably, HIV-1 inhibitor-40 shows no significant acute toxicity in vivo, making it a promising candidate for further research in HIV treatment. -
HIV Inhibitor
Influenza antiviral conjugate-1 (INT-2) is an HIV inhibitor that exhibits potent cell fusion inhibition. This compound serves as a click chemistry reagent, featuring an alkyne group capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its application in biological research allows for the development of innovative therapeutic strategies and the study of viral entry mechanisms. -
HIV REV/RRE Interaction Inhibitor
Niruriside is an inhibitor of the HIV REV/RRE complex, specifically targeting the interaction between the HIV REV protein and RRE RNA with an IC50 of 3.3 μM. This compound exhibits selectivity, showing no significant effects on the unrelated R17 capsid protein/operator RNA binding system. While Niruriside does not protect CEM-SS cells from acute HIV-1 infection, it serves as a valuable tool for investigating the mechanisms of HIV infection and the role of the REV/RRE interaction in viral replication and pathogenesis. -
HIV
4-Isocyanato-TEMPO is a spin labeling reagent that targets the 2'-position of RNA. This compound is instrumental in studying the dynamics of HIV-1 transactivation response RNA and hammerhead ribozyme interactions through electron paramagnetic resonance (EPR) spectroscopy. Its unique properties enable detailed investigation of RNA structures and dynamics, making it valuable in HIV research and related biochemical studies. -
HIV-1 Inhibitor
L 696229 is a selective inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), demonstrating significant antiviral activity. This compound is primarily utilized in the study of HIV replication and the development of antiretroviral therapies, offering insights into viral resistance mechanisms and potential therapeutic interventions. Its specificity for RT makes it a valuable tool in HIV research and drug discovery. -
HIV-1 Inhibitor
Fosamprenavir sodium is an orally active inhibitor targeting HIV-1 protease and functions as a prodrug for Amprenavir. Upon administration, it is hydrolyzed by cell phosphatases in the intestinal epithelium to release Amprenavir, which inhibits HIV-1 protease by binding to its active site. This binding prevents the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the maturation of infectious virus particles. Fosamprenavir sodium is valuable for research on human immunodeficiency virus (HIV-1) infection. -
Anti-HIV Activity
Interiorin is a compound derived from Kadsura heteroclita that exhibits moderate anti-HIV activity, characterized by an EC50 value of 1.6 µg/mL. This bioactive compound is of interest in antiviral research, particularly for the development of therapeutic strategies against HIV infection. Its potential to modulate viral replication makes it a valuable reagent for studies focused on HIV biology and treatment options. -
Non-Nucleoside rReverse Transcriptase Inhibitor
UC-38 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent anti-HIV activity. This compound disrupts the reverse transcription process essential for the viral replication cycle, making it a valuable tool for research on HIV mechanisms and potential therapeutics. Its application extends to the investigation of NNRTIs in the development of effective HIV treatment strategies.
